DEFA14A: STAAR Board Urges Vote For Alcon Merger Amid Opposition

STAAR Surgical's Board reiterates its unanimous recommendation for stockholders to approve the Alcon merger, disagreeing with a Glass Lewis report and highlighting a 59% premium.

Summary

• STAAR Surgical's Board of Directors unanimously recommends stockholders vote FOR the Alcon merger agreement.
• The Board strongly disagrees with the recommendation issued by Glass, Lewis & Co., LLC.
• Alcon is offering an all-cash payment of $28.00 per share to STAAR stockholders.
• This offer represents a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) prior to the announcement.
• Broadwood's proposal to vote down the merger could allow them to take control without paying a premium to other stockholders.
• The definitive proxy statement on Schedule 14A was filed with the SEC and first sent to stockholders on September 16, 2025.

Sentiment

Score: 8

Explanation: The filing strongly advocates for the merger, presenting it as highly beneficial for stockholders due to the significant premium and de-risking of future prospects. It clearly outlines the negative consequences of not approving the deal, indicating a very positive outlook on the merger's success and impact.

Positives

• Stockholders receive a certain and immediate cash value of $28.00 per share.
• The offer represents a significant premium of 59% over the 90-day VWAP.
• The merger provides an attractive valuation multiple.
• The deal de-risks STAAR's standalone plan and addresses existing headwinds.
• The merger is expected to accelerate ICL adoption by more surgeons for the benefit of more patients worldwide.
• The merger was unanimously recommended and approved by STAAR's independent and experienced Board.

Negatives

• Voting against the merger could lead to considerable downward pressure on STAAR's valuation.
• A 'no' vote risks STAAR's future direction being controlled by a single minority stockholder (Broadwood) at the expense of the majority.
• There is a risk of creeping control by Broadwood, which is identified as a likely drag on valuation.
• Ongoing risks related to STAAR's standalone prospects would persist if the merger fails.
• Broadwood's proposal threatens the dismissal of the existing Board and management, with a new team hand-picked by Broadwood.
• A failed merger would cause lengthy and significant disruption to patients, surgeons, employees, distributors, partners, and stockholders.

Risks

• The occurrence of any event, change, or circumstances that could lead to the termination of the Alcon merger agreement or delay/failure of the transaction.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and partners.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• Outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• Ongoing risks related to STAAR's standalone prospects if the merger does not proceed.
• Risk of creeping control by Broadwood if the merger is voted down, potentially dragging down valuation.

Future Outlook

The merger is expected to accelerate the adoption of ICLs by more surgeons for the benefit of more patients worldwide. It also aims to de-risk STAAR's standalone plan and address existing headwinds.

Management Comments

• "The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis."
• "We urge all STAAR stockholders to protect their investment and vote FOR the Alcon merger on the WHITE proxy card TODAY."
• "Alcon is paying STAAR stockholders a 59% premium to the 90-day VWAP, whereas Broadwood's proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders."

Industry Context

STAAR Surgical is positioned as the global leader in phakic IOLs with its EVO ICL product line, a vision correction solution. The proposed merger with Alcon, a major player in eye care, suggests a strategic consolidation within the ophthalmic surgery market, potentially enhancing the reach and adoption of STAAR's technology through Alcon's broader distribution and resources.

Stakeholder Impact

• Shareholders: Expected to receive a significant cash premium of $28.00 per share, providing immediate and certain value. Risk of significant stock price decline if the merger is not consummated.
• Patients and Surgeons: The merger is anticipated to accelerate ICL adoption, benefiting more patients worldwide by making vision correction more accessible.
• Employees, Distributors, and Partners: Face potential lengthy and significant disruption if the merger fails, impacting relationships and operations.
• Management: The existing Board and management face threatened dismissal if Broadwood's proposal to vote down the merger succeeds.

Next Steps

• Stockholders are urged to vote FOR the Alcon merger on the WHITE proxy card.
• Obtain required regulatory approvals.
• Satisfy other closing conditions for the completion of the proposed transaction.

Key Dates

Recommendation

The filing strongly recommends accepting the Alcon merger, which offers a substantial 59% premium over the 90-day VWAP, translating to a certain and immediate cash value of $28.00 per share. This represents a compelling exit for stockholders, de-risking standalone prospects and providing an attractive valuation multiple. The alternative, as presented, involves significant downside risks including valuation pressure, potential loss of control to a minority stockholder, and operational disruption. For an investor, accepting this premium offer is a clear financial benefit.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Proxy Statement, EVO ICL, Phakic IOLs, Vision Correction, Stockholder Vote, Corporate Governance, Ophthalmology